|
|
 |
|
Viewing report
|
|
|
|
Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010
Global Markets Direct, Dec 2010, Pages: 128
Chronic Myelocytic Leukemia (CML) - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “Chronic Myelocytic Leukemia Pipeline Review, Q4 2010”, provides an overview of the Chronic Myelocytic Leukemia therapeutic pipeline. This report provides information on the therapeutic development for Chronic Myelocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia. “Chronic Myelocytic Leukemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia.
- A review of the Chronic Myelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for Chronic Myelocytic Leukemia.
- A review of the Chronic Myelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Myelocytic Leukemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
|
|
|
|
